Cover Image

Development of a gene expression-based prognostic signature for IDH wild-type glioblastoma

We aimed to develop a gene expression-based prognostic signature for isocitrate dehydrogenase (IDH) wild-type glioblastoma using clinical trial datasets representative of glioblastoma clinical trial populations.Samples were collected from newly diagnosed patients with IDH wild-type glioblastoma in t...

Full description

Saved in:
Bibliographic Details
Main Authors: Johnson, Radia (Author) , Phillips, Heidi S (Author) , Bais, Carlos (Author) , Brennan, Cameron W (Author) , Cloughesy, Timothy F (Author) , Daemen, Anneleen (Author) , Herrlinger, Ulrich (Author) , Jenkins, Robert B (Author) , Lai, Albert (Author) , Mancao, Christoph (Author) , Weller, Michael (Author) , Wick, Wolfgang (Author) , Bourgon, Richard (Author) , Garcia, Josep (Author)
Format: Article (Journal)
Language:English
Published: 8 September 2020
In: Neuro-Oncology
Year: 2020, Volume: 22, Issue: 12, Pages: 1742-1756
ISSN:1523-5866
DOI:10.1093/neuonc/noaa157
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1093/neuonc/noaa157
Get full text
Author Notes:Radia M. Johnson, Heidi S. Phillips, Carlos Bais, Cameron W. Brennan, Timothy F. Cloughesy, Anneleen Daemen, Ulrich Herrlinger, Robert B. Jenkins, Albert Lai, Christoph Mancao, Michael Weller, Wolfgang Wick, Richard Bourgon, and Josep Garcia
Description
Summary:We aimed to develop a gene expression-based prognostic signature for isocitrate dehydrogenase (IDH) wild-type glioblastoma using clinical trial datasets representative of glioblastoma clinical trial populations.Samples were collected from newly diagnosed patients with IDH wild-type glioblastoma in the ARTE, TAMIGA, EORTC 26101 (referred to as “ATE”), AVAglio, and GLARIUS trials, or treated at UCLA. Transcriptional profiling was achieved with the NanoString gene expression platform. To identify genes prognostic for overall survival (OS), we built an elastic net penalized Cox proportional hazards regression model using the discovery ATE dataset. For validation in independent datasets (AVAglio, GLARIUS, UCLA), we combined elastic net-selected genes into a robust z-score signature (ATE score) to overcome gene expression platform differences between discovery and validation cohorts.NanoString data were available from 512 patients in the ATE dataset. Elastic net identified a prognostic signature of 9 genes (CHEK1, GPR17, IGF2BP3, MGMT, MTHFD1L, PTRH2, SOX11, S100A9, and TFRC). Translating weighted elastic net scores to the ATE score conserved the prognostic value of the genes. The ATE score was prognostic for OS in the ATE dataset (P < 0.0001), as expected, and in the validation cohorts (AVAglio, P < 0.0001; GLARIUS, P = 0.02; UCLA, P = 0.004). The ATE score remained prognostic following adjustment for O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation status and corticosteroid use at baseline. A positive correlation between ATE score and proneural/proliferative subtypes was observed in patients with MGMT non-methylated promoter status.The ATE score showed prognostic value and may enable clinical trial stratification for IDH wild-type glioblastoma.
Item Description:Im Text ist "IDH" kursiv geschrieben
Gesehen am 07.05.2022
Physical Description:Online Resource
ISSN:1523-5866
DOI:10.1093/neuonc/noaa157

Similar Items